129 related articles for article (PubMed ID: 11366357)
1. Some existing drugs work on resistant HIV.
AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
[TBL] [Abstract][Full Text] [Related]
2. Coming therapies: amprenavir.
Gatell J
Int J Clin Pract Suppl; 1999 Jun; 103():42-4. PubMed ID: 10622044
[TBL] [Abstract][Full Text] [Related]
3. Amprenavir study results released.
AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
[No Abstract] [Full Text] [Related]
4. Double protease inhibitor regimens with amprenavir show promise.
AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
[No Abstract] [Full Text] [Related]
5. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
6. A lame duck, a dark horse, and a goat.
Huff B
GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
[No Abstract] [Full Text] [Related]
7. New drugs in development.
Proj Inf Perspect; 1998 Sep; (25):8. PubMed ID: 11365851
[TBL] [Abstract][Full Text] [Related]
8. Amprenavir approved.
STEP Perspect; 1999; 99(2):8. PubMed ID: 11366753
[TBL] [Abstract][Full Text] [Related]
9. Tipranavir (Aptivus) for HIV.
Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341
[TBL] [Abstract][Full Text] [Related]
10. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection.
Margolis DM; Mukherjee AL; Fletcher CV; Hogg E; Ogata-Arakaki D; Petersen T; Rusin D; Martinez A; Mellors JW
AIDS; 2007 Oct; 21(15):2025-32. PubMed ID: 17885292
[TBL] [Abstract][Full Text] [Related]
11. Phase III results of second-generation HIV protease inhibitor reported.
Oncology (Williston Park); 1998 Nov; 12(11):1616. PubMed ID: 9834939
[No Abstract] [Full Text] [Related]
12. Amprenavir may be less cross-resistant with other PIs.
Murphy MJ
HIV Clin; 1999; 11(5):1, 7. PubMed ID: 11810849
[No Abstract] [Full Text] [Related]
13. Tipranavir: the first nonpeptidic protease inhibitor.
Cheonis N
BETA; 2004; 16(2):15-7. PubMed ID: 15104065
[TBL] [Abstract][Full Text] [Related]
14. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
15. Reviving protease inhibitors: new data and more options.
Murphy RL
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
[No Abstract] [Full Text] [Related]
16. Tipranavir in the protease inhibitors arena.
Vergani B; Rusconi S
Drugs R D; 2011 Dec; 11(4):291-3. PubMed ID: 22133386
[No Abstract] [Full Text] [Related]
17. Protease inhibitors: the current status.
Dauer B
J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
[No Abstract] [Full Text] [Related]
18. DAPD (Emory University/Triangle Pharmaceuticals/Abbott Laboratories).
Corbett AH; Rublein JC
Curr Opin Investig Drugs; 2001 Mar; 2(3):348-53. PubMed ID: 11575703
[TBL] [Abstract][Full Text] [Related]
19. New drugs: amprenavir and abacavir.
TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
